Restart Life Sciences Announces Closing First Tranche of Financing

Rhea-AI Summary

Restart Life Sciences (OTC Pink: NMLSF) closed the first tranche of a non-brokered private placement on December 5, 2025, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit. Each unit includes one common share and one one-year warrant exercisable at CAD$0.10. The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants exercisable at CAD$0.10 for one year. Proceeds are intended for health food trials, potential acquisitions, and general working capital. All securities are subject to a hold period ending April 6, 2026.

Positive

• Raised CDN$500,000 in first tranche financing
• Issued 5,000,000 units at CAD$0.10 each
• Proceeds allocated to health food trials and acquisitions

Negative

• Potential dilution of 5,060,000 additional shares via warrants
• Paid CAD$16,800 cash in finder's fees
• Warrants exercisable at low strike of CAD$0.10 for one year

News Market Reaction

+27.06%

1 alert

+27.06% News Effect

On the day this news was published, NMLSF gained 27.06%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Gross proceeds: CDN$500,000 Units issued: 5,000,000 units Unit price: CDN$0.10 +5 more

8 metrics

Gross proceeds CDN$500,000 First tranche non-brokered private placement

Units issued 5,000,000 units Private placement at CDN$0.10 per unit

Unit price CDN$0.10 Pricing of private placement units

Finder fees (cash) CAD$16,800 Cash finder’s fees paid for placement

Finder warrants 60,000 warrants Non-transferable finder warrants issued

Warrant exercise price CAD$0.10 Exercise price for one-year warrants and finder warrants

Warrant term 1 year Exercise period for placement and finder warrants

Hold period expiry April 6, 2026 Hold period of four months and one day on securities

Market Reality Check

Price: $0.0857 Vol: Volume 2,008 is at 0.59x ...

low vol

$0.0857 Last Close

Volume Volume 2,008 is at 0.59x the 20-day average of 3,397 shares. low

Technical Price 0.08051 is trading above the 200-day MA at 0.06.

Peers on Argus

While NMLSF traded at -4.47% pre-news, most biotech peers were flat, with only C...

While NMLSF traded at -4.47% pre-news, most biotech peers were flat, with only CPMV showing notable upside at +18.97%, suggesting stock-specific factors rather than a broad sector move.

Historical Context

1 past event · Latest: Dec 05 (Neutral)

1 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	Financing tranche close	Neutral	+27.1%	Closed first tranche of non-brokered private placement raising CDN$500,000.

Recent Company History

On December 5, 2025, Restart Life Sciences reported closing the first tranche of a non-brokered private placement, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit, each with a one-year warrant at CAD$0.10. The stock’s documented +27.06% reaction over the following 24 hours shows that this capital raise coincided with a strong positive move despite the dilutive nature of the financing.

Market Pulse Summary

The stock surged +27.1% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +27.1% in the session following this news. A strong positive reaction aligns with the documented +27.06% move after this financing news, indicating that investors previously treated the capital raise as constructive despite dilution. The issuance of 5,000,000 new units and additional warrants increased potential share supply, which can cap upside once initial enthusiasm fades. With relatively low recent trading volume of 2,008 shares pre-news, any sharp gains could have been vulnerable to consolidation as liquidity normalized.

Key Terms

private placement, warrant

2 terms

private placement financial

"the Company has closed the first tranche of its non-brokered private placement"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

warrant financial

"one transferable common share purchase warrant (each, a "Warrant")"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

AI-generated analysis. Not financial advice.

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement").

Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a price of CDN$0.10 per Unit. Each Unit consists of one common share and one transferable common share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one additional common share for a period of one (1) year at a price of CAD $0.10 per common share.

In connection with the Placement, the Company paid cash finder's fees totaling CAD $16,800 and issued 60,000 non-transferable finder warrants (each, a "Finder Warrant") to certain eligible arm's-length finders who introduced subscribers to the Placement. Each Finder Warrant entitles the holder to purchase one common share for a period of one (1) year at a price of CAD $0.10 per common share.

The Company intends to use the proceeds from the Offering towards health food trials, potential acquisitions, and general working capital. All securities issued under the Placement are subject to a hold period of four months and one day expiring on April 6, 2026.

About Restart Life Sciences Corp.
Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.

On behalf of the Board of Directors
Steve Loutskou
Chief Executive Officer, Restart Life Sciences Corp.
Tel: +1 (778) 819-0244
Email: hello@restartlife.co

Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Sciences' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277058

FAQ

What did Restart Life Sciences (NMLSF) announce on December 5, 2025?

Restart Life closed a CDN$500,000 first tranche private placement issuing 5,000,000 units at CAD$0.10 per unit.

How are the units structured in Restart Life's NMLSF financing?

Each unit contains one common share plus one transferable warrant exercisable at CAD$0.10 for one year.

What is the hold period and expiry date for securities from Restart Life's placement (NMLSF)?

All securities are subject to a four-month-and-one-day hold period ending on April 6, 2026.

How will Restart Life (NMLSF) use the proceeds from the CDN$500,000 placement?

The company intends to use proceeds for health food trials, potential acquisitions, and general working capital.

What finder compensation did Restart Life pay in the NMLSF placement?

The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants.

How much potential dilution could Restart Life (NMLSF) face from this financing?

Warrants issued could convert to 5,060,000 additional shares (5,000,000 unit warrants plus 60,000 finder warrants) at CAD$0.10 within one year.